Proactive Investors - Run By Investors For Investors

WideCells strengthens management and advisory team as it embarks on a “new period of growth”

WideCells has brought in three new non-execs, created a Scientific Advisory Committee and appointed WG Partners as joint broker
doctor discussing stem cell treatment
WideCells offers various stem cell-related services, including insurance, education and storage and processing

As part of its transition from product development into a revenue-generative company, stem cell services provider WideCells Group PLC (LON:WDC) has beefed up its management and advisory team.

The London-listed group has added Peter Presland, Malcolm Glaister and Zakaria Aziz to its board as non-executive directors. Presland will be WideCells’ new chairman after the company confirmed Graham Hine has retired from the role.

WATCH: WideCells strengthens management and advisory team

The three new additions will all “bring a wealth of corporate experience”, WideCells said in Thursday’s statement.

Alongside the new board additions, WideCells has also created a Scientific Advisory Committee which will identify and advise the board on new developments within the stem cell sector.

The committee, which will be chaired by professor Tristan Mckay, will also help manage all research work for the group.

‘A new period of growth’

“With three divisions now operational and starting to generate revenues, we are about to embark on a new period of growth and development as we look to build our operational reach on an international scale, increase our client base, and ultimately transform the value profile of our company,” said chief executive João Andrade.

READ: WideCells Group formally inks revenue generating overseas deal

“We have welcomed three new board members, who bring a wealth of corporate knowledge and experience in the insurance, medical and financial industries, which will be invaluable to us as we target new markets and seek new commercial agreements to facilitate the roll-out of our stem cell services.

“To support this new board, and in line with our commitment to maintaining operational excellence and being at the fore of our field, we have also created a new Scientific Advisory Committee, which brings together some of the best brains in stem cell technology and regenerative medicine.

READ: WideCells expands its reach to Spain

“The committee's unrivalled knowledge and prestigious network of contacts will I believe provide us with a number of exciting growth opportunities.”

WideCells also said it had appointed WG Partners as its joint broker as it looks to raise its institutional profile.

View full WDC profile View Profile

WideCells Group Timeline

Related Articles

CBD oil
November 15 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use